Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at firstname.lastname@example.org.
Adjuvant Olaparib Approved in European Union for BRCA1/2-Positive, HER2-Negative High-Risk Early Breast CancerAugust 5th 2022
The European Commission approved olaparib as monotherapy or in combination with endocrine therapy for patients with germline BRCA1/2-mutant, HER2-negative high-risk early breast cancer.
FDA Approves Trastuzumab Deruxtecan in Unresectable or Metastatic HER2-Low Breast CancerAugust 5th 2022
Based on results from the phase 3 DESTINY-Breast04 trial, the FDA has approved fam-trastuzumab deruxtecan-nxki as an intravenous infusion for patients with unresectable or metastatic HER2-low breast cancer.
Pembrolizumab and Chemotherapy Does Not Meet Primary End Points Despite Modest OS, rPFS Improvement in mCRPCAugust 4th 2022
Results from the phase 3 KEYNOTE-921 trial showed the primary end points of overall survival and radiographic progression-free survival were not met despite a trend towards improvement following treatment with pembrolizumab and docetaxel in patients with metastatic castration-resistant prostate cancer.
Phase 3 INTERLINK-1 Trial of Monalizumab Plus Cetuximab in Recurrent or Metastatic HNSCC DiscontinuedAugust 3rd 2022
Findings from the planned futility interim analysis of the phase 3 INTERLINK-1 trial has led to the study’s termination after monalizumab and cetuximab did not meet efficacy end points in recurrent or metastatic squamous cell carcinoma in the head and neck.
Subcutaneous Vs IV Atezolizumab Demonstrates Non-Inferior Pharmacokinetics in Advanced NSCLCAugust 3rd 2022
Results from the phase 3 IMscin001 trial indicated that atezolizumab given subcutaneously vs intravenously yielded non-inferior pharmacokinetics for patients with immunotherapy-naïve locally advanced or metastatic non–small cell lung cancer.
FDA Accepts BLA And Grants Priority Review to Omidubicel in Hematologic MalignanciesAugust 2nd 2022
Based on results from a phase 3 trial, the FDA has accepted a biologics license application for and granted priority review to omidubicel for those with hematologic malignancies who require allogenic hematopoietic stem cell transplant.
Addition of Elotuzumab to KRd Yields Promising Responses in Newly Diagnosed Multiple MyelomaAugust 1st 2022
Results from a phase 2 study indicated that adding elotuzumab to carfilzomib, lenalidomide, and dexamethasone with a minimal residual disease–adapted design boosted responses for those with newly diagnosed multiple myeloma.
Clinical Unmasking May Cause Increased Rates of High-Grade Cervical Neoplasia From Non–Vaccine Preventable HPVAugust 1st 2022
Investigators reported that vaccinated patients had a higher rate of grade 2/3 cervical neoplasia due to non–vaccine preventable human papillomavirus compared with unvaccinated patients, an event commonly termed clinical unmasking.
Radiotherapy Induced Taste Dysfunction During and 3 Months After Treatment in Head and Neck CancerAugust 1st 2022
Treatment with radiotherapy for head and neck cancer resulted in taste dysfunction during treatment and 3 months thereafter, although reduction in oral cavity intensity-modulated radiotherapy dose may result in early taste function recovery.
Niraparib Plus Ipilimumab Yields Enhanced 6-Month PFS vs Niraparib Plus Nivolumab in Advanced Pancreatic CancerJuly 31st 2022
Results from a phase 1b/2 trial indicated that niraparib plus nivolumab yielded superior progression-free survival at 6 months vs niraparib and ipilimumab for patients with platinum-sensitive advanced pancreatic cancer.
Samer A. Srour, MB, ChB, MS, Discusses Umbilical Cord Blood-Derived Natural Killer Cell Combination as a Potential Strategy for High-Risk Multiple MyelomaJuly 29th 2022
Elotuzumab, lenalidomide, high-dose melphalan, as well as umbilical cord blood–derived natural killer cells and autologous stem cell transplant demonstrated tolerability and improved transplant outcomes for high-risk multiple myeloma.
Findings Support Liso-Cel in the Second-Line for Large B-Cell Lymphoma Not Intended for HSCTJuly 28th 2022
Findings from the phase 2 TRANSCEND-PILOT-017006 supported the use of lisocabtagene maraleucel as a second-line treatment for patients with large B-cell lymphoma who were not able to or didn’t want to receive hematopoietic stem cell transplant.
Comparison of Multimodal Therapies Identifies Equivalent Mortality Outcomes, Improved Distant Metastases in High-Risk Prostate CancerJuly 26th 2022
Radical proctectomy, external beam radiotherapy, and brachytherapy yielded comparable prostate cancer–specific mortality, while external beam radiotherapy with or without brachytherapy resulted in favorable distant metastases outcomes in patients with high-risk prostate cancer.
Enfortumab Vedotin Plus Pembrolizumab Yield Promising Results in Advanced Urothelial CarcinomaJuly 26th 2022
Results from cohort K of the phase 1b/2 KEYNOTE-869 trial showed improved responses for patients with advanced or metastatic urothelial carcinoma when treated with enfortumab vedotin-efjv plus pembrolizumab.
Fulvestrant Plus Capivasertib Improved Survival Vs Fulvestrant/Placebo in ER+, HER2– Advanced Breast CancerJuly 25th 2022
Findings from the phase 1/2 FAKTION trial indicated that survival had increased following the addition of capivasertib to fulvestrant for patients with aromatase inhibitor–resistant, estrogen receptor–positive, HER2-negative advanced breast cancer.
Primary End Points Not Met in Phase 3 OVAL Trial of Ofra-Vec Plus Paclitaxel in Advanced Ovarian CancerJuly 22nd 2022
The primary end points of progression-free survival and overall survival were not met in the phase 3 OVAL trial assessing ofranergene obadenovec for patients with platinum-resistant ovarian cancer.
Adequate Antibody Responses Reported After COVID-19 mRNA-1273 Vaccination During Chemotherapy/Immunotherapy Treatment for Solid TumorsJuly 21st 2022
Patients with solid tumors undergoing treatments with chemotherapy, immunotherapy, or chemoimmunotherapy mounted an adequate antibody response to the mRNA-1273 COVID-19 vaccine.
Pegasparaginase-Based Chemotherapy Yields Promising Preliminary Results in Extranodal Natural Killer/T-Cell LymphomaJuly 21st 2022
Dexamethasone, Cisplatin, gemcitabine, and pegaspargase resulted in improved preliminary outcomes vs dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide for patients with newly diagnosed locally advanced stage III or IV extranodal natural killer/ T-cell lymphoma.
Medicaid Associated With Reduction in Racial/Ethnic Disparities in De Novo Stage IV Breast CancerJuly 19th 2022
Investigators reported a reduction in racial and ethnic disparities among patients with de novo stage IV breast cancer following implementation of Medicaid expansion, and included a decreased risk of death for patients in a racial/ethnic minority compared with White patients.
Atezolizumab Plus Bevacizumab Induces Promising Clinical Responses in Neuroendocrine TumorsJuly 19th 2022
Patients with pancreatic and extrapancreatic neuroendocrine tumors treated with atezolizumab plus bevacizumab experienced consistent clinical responses and a progression-free survival consistent with other therapies.
FDA Delays Decision of Tislelizumab Monotherapy for Previously Treated Unresectable Advanced or Metastatic ESCCJuly 14th 2022
The FDA has delayed the decision to approve tislelizumab monotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma following prior systemic therapy, due to COVID-19 travel restrictions.